Register for our free email digests:
Latest From Sanofi
Keeping Track: Merck's Follow-On Insulin Edges Closer To Market; Braeburn Submits Another Buprenorphine Depot
The latest drug development news and highlights from our FDA Performance Tracker.
Jury verdict comes seven years after Momenta/Sandoz launched generic version of Lovenox; firms sought treble damages from Amphastar for willful infringement of manufacturing process patent.
The European Medicines Agency’s key scientific committee, the CHMP, has recommended for approval throughout Europe a total of 11 new drugs. Two medicines received a negative opinion from the committee and the marketing authorization application for one product has been withdrawn. A further eight products are set to receive indication extensions. The medicines that got positive opinions are likely to secure official approval within the next few months.
While Dupixent looks set for use in Europe for treating moderate-to-severe atopic dermatitis, analysts believe the biologic has a great future in other indications and could eventually become a blockbuster.
- Synthesis Technologies, Production Processes
- Large Molecule
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Valneva SE
- Senior Management
Thomas Lingelbach , Pres. & CEO
Reinhard Kandera, CFO
- Contact Info
Phone: (33) 4 78 76 61 01
10-12 boulevard Marius Vivier Merle
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.